CYC065 is the real future of Cyclacel. Big pharmas are very interested in getting CDK inhibitors approved for cancer. Big pharmas that focus on oncology and are not in the CDK arena and want in will be the ones most likely to buy this small company for just this asset. Pfizer will soon gain approval for their CDK4/6 inhibitor based on phase 2 data and that is when the real excitement begins. Cyclacel's CYC065 appears to have a very clean profile and the sooner someone makes a move for it, the less likely someone else will get it. CYC065 is Cyclacel's most valuable asset.
News 
Market Data 
Discover 
